報價延遲最少15分鐘:2024/12/24 13:11 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.378 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-6.97/-10.80
|
|
企業價值
4.47M
|
| 資產負債 |
|
每股賬面淨值
0.12
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 13:11 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. |